Alpha 2.0
Login Register
» Authors » Vinicius Carrera Souza

Vinicius Carrera Souza

Explore the profile of Vinicius Carrera Souza including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 40
Followers 0
Related Specialties
Oncology
Urology
Pharmacology
Top 10 Co-Authors
Andrey Soares
Daniel Herchenhorn
Diogo Assed Bastos
Andre Deeke Sasse
Fernando Cotait Maluf
Roni de Carvalho Fernandes
Karine Martins da Trindade
Fernando Sabino Marques Monteiro
Rodolfo Borges Dos Reis
Igor Alexandre Protzner Morbeck
Published In
Clin Genitourin Cancer
Int Braz J Urol
J Cancer Res Clin Oncol
Cancer Immunol Immunother
Pathol Int
Affiliations
Soon will be listed here.
Recent Articles
1.
Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer: Secondary Analysis of a Randomized Clinical Trial
Bastos D, Soares A, Schutz F, Cronemberger E, de Almeida Luz M, Martins S, et al.
JAMA Netw Open . 2025 Jan; 8(1):e2454253. PMID: 39804646
Importance: The open-label randomized phase 2 LACOG0415 trial evaluated 3 treatment strategies for patients with advanced castration-sensitive prostate cancer (CSPC): androgen deprivation therapy (ADT) plus abiraterone acetate and prednisone (AAP),...
2.
The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population
Souza V, Marques Monteiro F, Maluf F, Werutsky G, Fabricio V, Gidekel R, et al.
Clin Genitourin Cancer . 2024 Aug; 22(5):102174. PMID: 39181783
Introduction: Fibroblast growth factor receptor (FGFR) mutations and fusions are relevant biomarkers in metastatic urothelial carcinoma (mUC). However, the prevalence of genomic alterations and their impact on clinical outcomes in...
3.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Massari F, Santoni M, Takeshita H, Okada Y, Tapia J, Basso U, et al.
Cancer Immunol Immunother . 2024 Apr; 73(6):106. PMID: 38634928
Background: Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or...
4.
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
Soares A, Marques Monteiro F, da Trindade K, Silva A, Cardoso A, Sasse A, et al.
J Cancer Res Clin Oncol . 2024 Apr; 150(4):183. PMID: 38594593
Purpose: Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however,...
5.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios G, et al.
Cancer Immunol Immunother . 2023 Sep; 72(11):3665-3682. PMID: 37676282
Background: Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of...
6.
"Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil"
Jardim D, Silva A, Pompeo A, Sarkis A, Cardoso A, Sasse A, et al.
Clin Genitourin Cancer . 2022 Oct; 21(2):e58-e69. PMID: 36266221
Introduction: Non-metastatic, castration-resistant prostate cancer (nmCRPC) is an important clinical stage of prostate cancer, prior to morbidity and mortality from clinical metastases. In particular, the introduction of novel androgen-receptor signaling...
7.
A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)
Monteiro F, Soares A, Souza V, Sperandio R, Grande E, Santoni M, et al.
Clin Genitourin Cancer . 2022 May; 20(5):391-398. PMID: 35595632
Nivolumab, a PD-1 ICI has been recently approved for the adjuvant treatment of high-risk MIUC patients. However, conflicting data from another randomized controlled trial (RCT) with atezolizumab makes the benefit...
8.
Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries
Pereira F, Silva A, Dettino A, Cardoso A, Sasse A, Kann A, et al.
JCO Glob Oncol . 2021 Apr; 7:545-549. PMID: 33856892
Purpose: To present a summary of the recommendations for the treatment and follow-up for the biochemical recurrence of castration-resistant prostate cancer (PCa) as acquired through a questionnaire administered at the...
9.
Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities
Maluf F, Soares A, Avanco G, Hada A, Cardoso A, Carneiro A, et al.
Int Braz J Urol . 2020 Dec; 47(2):359-373. PMID: 33284538
Background: Non-metastatic castration resistant prostate cancer (M0 CRPC) has seen important developments in drugs and diagnostic tools in the last two years. New hormonal agents have demonstrated improvement in metastasis...
10.
Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG)
Soares A, Marques Monteiro F, Maluf F, Bastos D, Jardim D, Sasse A, et al.
J Cancer Res Clin Oncol . 2020 May; 146(7):1829-1845. PMID: 32410064
Purpose: The outcome of RCC has improved considerably in the last few years, and the treatment options have increased. LACOG-GU and LARCG held a consensus meeting to develop guidelines to...